Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study Clinical trials frequently include multiple end points that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results